Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.

To evaluate the prognostic impact of the lymph node ratio (LNR) in ypStage III rectal cancer patients who were treated with neoadjuvant chemoradiotherapy (NCRT).We retrospectively reviewed the data of 638 consecutive patients who underwent NCRT followed by total mesorectal excision, and postoperativ...

Full description

Bibliographic Details
Main Authors: Taeryool Koo, Changhoon Song, Jae-Sung Kim, Kyubo Kim, Eui Kyu Chie, Sung-Bum Kang, Keun-Wook Lee, Jee Hyun Kim, Seung-Yong Jeong, Tae-You Kim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4575157?pdf=render
_version_ 1828858060566691840
author Taeryool Koo
Changhoon Song
Jae-Sung Kim
Kyubo Kim
Eui Kyu Chie
Sung-Bum Kang
Keun-Wook Lee
Jee Hyun Kim
Seung-Yong Jeong
Tae-You Kim
author_facet Taeryool Koo
Changhoon Song
Jae-Sung Kim
Kyubo Kim
Eui Kyu Chie
Sung-Bum Kang
Keun-Wook Lee
Jee Hyun Kim
Seung-Yong Jeong
Tae-You Kim
author_sort Taeryool Koo
collection DOAJ
description To evaluate the prognostic impact of the lymph node ratio (LNR) in ypStage III rectal cancer patients who were treated with neoadjuvant chemoradiotherapy (NCRT).We retrospectively reviewed the data of 638 consecutive patients who underwent NCRT followed by total mesorectal excision, and postoperative adjuvant chemotherapy for rectal cancer from 2004 to 2011. Of these, 125 patients were positive for lymph node (LN) metastasis and were analyzed in this study.The median numbers of examined and metastatic LNs were 17 and 2, respectively, and the median LNR was 0.143 (range, 0.02-1). Median follow-up time was 55 months. In multivariate analyses, LNR was an independent prognostic factor for overall survival (OS) (hazard ratio [HR] 2.17, p = 0.041), disease-free survival (DFS) (HR 2.28, p = 0.005), and distant metastasis-free survival (DMFS) (HR 2.30, p = 0.010). When ypN1 patients were divided into low (low LNR ypN1 group) and high LNR (high LNR ypN1 group) according to a cut-off value of 0.152, the high LNR ypN1 group had poorer OS (p = 0.043) and DFS (p = 0.056) compared with the low LNR ypN1 group. And there were no differences between the high LNR ypN1 group and the ypN2 group in terms of the OS (p = 0.703) and DFS (p = 0.831).For ypN-positive rectal cancer patients, the LNR was a more effective prognostic marker than the ypN stage, circumferential resection margin, or tumor regression grade after NCRT, and could be used to discern the high-risk group among ypN1 patients.
first_indexed 2024-12-13T01:49:15Z
format Article
id doaj.art-d4cdc33171ea487ba95ce9c5b778644e
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T01:49:15Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-d4cdc33171ea487ba95ce9c5b778644e2022-12-22T00:03:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01109e013872810.1371/journal.pone.0138728Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.Taeryool KooChanghoon SongJae-Sung KimKyubo KimEui Kyu ChieSung-Bum KangKeun-Wook LeeJee Hyun KimSeung-Yong JeongTae-You KimTo evaluate the prognostic impact of the lymph node ratio (LNR) in ypStage III rectal cancer patients who were treated with neoadjuvant chemoradiotherapy (NCRT).We retrospectively reviewed the data of 638 consecutive patients who underwent NCRT followed by total mesorectal excision, and postoperative adjuvant chemotherapy for rectal cancer from 2004 to 2011. Of these, 125 patients were positive for lymph node (LN) metastasis and were analyzed in this study.The median numbers of examined and metastatic LNs were 17 and 2, respectively, and the median LNR was 0.143 (range, 0.02-1). Median follow-up time was 55 months. In multivariate analyses, LNR was an independent prognostic factor for overall survival (OS) (hazard ratio [HR] 2.17, p = 0.041), disease-free survival (DFS) (HR 2.28, p = 0.005), and distant metastasis-free survival (DMFS) (HR 2.30, p = 0.010). When ypN1 patients were divided into low (low LNR ypN1 group) and high LNR (high LNR ypN1 group) according to a cut-off value of 0.152, the high LNR ypN1 group had poorer OS (p = 0.043) and DFS (p = 0.056) compared with the low LNR ypN1 group. And there were no differences between the high LNR ypN1 group and the ypN2 group in terms of the OS (p = 0.703) and DFS (p = 0.831).For ypN-positive rectal cancer patients, the LNR was a more effective prognostic marker than the ypN stage, circumferential resection margin, or tumor regression grade after NCRT, and could be used to discern the high-risk group among ypN1 patients.http://europepmc.org/articles/PMC4575157?pdf=render
spellingShingle Taeryool Koo
Changhoon Song
Jae-Sung Kim
Kyubo Kim
Eui Kyu Chie
Sung-Bum Kang
Keun-Wook Lee
Jee Hyun Kim
Seung-Yong Jeong
Tae-You Kim
Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
PLoS ONE
title Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
title_full Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
title_fullStr Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
title_full_unstemmed Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
title_short Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
title_sort impact of lymph node ratio on oncologic outcomes in ypstage iii rectal cancer patients treated with neoadjuvant chemoradiotherapy followed by total mesorectal excision and postoperative adjuvant chemotherapy
url http://europepmc.org/articles/PMC4575157?pdf=render
work_keys_str_mv AT taeryoolkoo impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT changhoonsong impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT jaesungkim impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT kyubokim impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT euikyuchie impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT sungbumkang impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT keunwooklee impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT jeehyunkim impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT seungyongjeong impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy
AT taeyoukim impactoflymphnoderatioononcologicoutcomesinypstageiiirectalcancerpatientstreatedwithneoadjuvantchemoradiotherapyfollowedbytotalmesorectalexcisionandpostoperativeadjuvantchemotherapy